Advertisement
Loading...

Grifols, S.A.

GRFS•NASDAQ
Healthcare
Drug Manufacturers - General
$7.66
$-0.13(-1.67%)
U.S. Market opens in 27h 12m

Grifols, S.A. (GRFS) Stock Overview

Explore Grifols, S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap6.5B
P/E Ratio10.80
EPS (TTM)$0.70
ROE0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$9.53
3 Months$10.86
1 Year Target$9.97

GRFS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Grifols, S.A. (GRFS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 39.39, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $9.97.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 10.80 and a market capitalization of 6.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.67%
5-Day Change
-6.13%
1-Month Change
-11.85%
3-Month Change
-17.81%
6-Month Change
-12.06%
Year-to-Date (YTD) Change
-18.07%
1-Year Change
-2.42%
3-Year Change
-14.51%
5-Year Change
-59.02%
All-Time (Max) Change
15.71%

Contact Information

https://www.grifols.com
34 93 571 02 21
Avinguda de la Generalitat, 152, Barcelona, NaN, 08174

Company Facts

23,833 Employees
IPO DateJun 2, 2011
CountryES
Actively Trading

Frequently Asked Questions